SHEET 04 OF 05 / FAQ
Common questions about the Wolverine blend, answered from the literature.
Direct answers to the questions that drive most of the search traffic for this stack.
What is the Wolverine peptide blend?
The Wolverine blend is a co-formulation of two research peptides — BPC-157, a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice, and TB-500, a synthetic 7-amino-acid fragment of thymosin beta-4 carrying the LKKTETQ actin-binding motif. The two peptides are administered together but do not form a single chemical complex; the blend is a co-formulation, not a fusion peptide. The nickname comes from the research community, referring to the perceived regenerative character of the combination. Neither compound is FDA-approved for any human indication, and the blend itself has no regulatory status as a combination product [16][18].
Why is it called the Wolverine stack?
The name is a community nickname for the perceived rapid-healing character of combining a peptide associated with angiogenesis and connective-tissue repair (BPC-157) with one associated with cell migration and re-epithelialization (TB-500). The label is descriptive shorthand, not a brand. Wolverine Clinic is an independent editorial project; it is not affiliated with Marvel Entertainment, the comic-book or film franchise, or any related trademark holder. Throughout this site the literal compound names are used in preference to the nickname wherever clarity permits.
What does the research say about combining BPC-157 and TB-500?
No controlled in-vivo study has directly compared the BPC-157 + TB-500 blend against either peptide administered alone. The combination rationale published in mechanism reviews is that the two peptides target non-overlapping pathways — BPC-157 supplies a VEGFR2 / Akt / eNOS angiogenesis and gastrointestinal cytoprotection mechanism, TB-500 supplies G-actin sequestration and cell migration via the LKKTETQ motif and integrin-linked kinase — and additive benefit is therefore plausible. Plausibility is not data. Every published outcome in either component's literature is from a single-agent experiment [4][5][9][10][18].
Is the Wolverine blend FDA-approved?
No. Neither BPC-157 nor TB-500 is approved by the U.S. Food and Drug Administration for any human indication, and the blend has no regulatory status as a combination product. In September 2023, the FDA placed both compounds on its Category 2 list of bulk drug substances of safety concern, which effectively prohibits 503A and 503B compounding pharmacies from producing them. The regulatory landscape has continued to evolve and the current status should be checked against the FDA's published lists [16].
Is TB-500 banned by WADA?
Yes. The World Anti-Doping Agency explicitly prohibits thymosin beta-4 and its derivatives — which includes TB-500 — at all times under category S2 (growth factors and growth-factor modulators). BPC-157 is also listed by WADA, under category S0 (non-approved substances), with effect from 2022. A Canadian athlete received a four-year sanction for TB-500 use. Any athlete subject to WADA testing should treat the Wolverine blend as prohibited [16].
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500, as sold for research, is a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) of thymosin beta-4, a 43-amino-acid endogenous peptide. The LKKTETQ motif is the actin-binding domain of the parent peptide, and most of the published mechanistic data — the PINCH/ILK complex formation, the cardiac repair work, the dermal wound studies, the ophthalmic trials — are on the 43-amino-acid parent rather than on the fragment specifically. Whether the fragment fully reproduces the parent peptide's pharmacology in vivo is not completely established [9][10][12][14].
How does BPC-157 work mechanistically?
Two main mechanisms are reported. First, BPC-157 promotes angiogenesis through activation of the Src–Caveolin-1–endothelial nitric oxide synthase (eNOS) pathway in vascular endothelium, with downstream effects on VEGFR2 signaling. In isolated rat aortic rings at 10–100 μg/mL, BPC-157 produced concentration-dependent vasodilation and released eNOS from caveolin-1 binding to roughly 50% of control [4]. Second, in vitro at 0.1–0.5 μg/mL it up-regulates growth hormone receptor expression in rat Achilles tendon fibroblasts by up to seven-fold by day three, sensitizing the cells to subsequent growth-hormone exposure [5]. These mechanisms are reported alongside down-regulation of NF-kB and pro-inflammatory cytokines TNF-alpha, IL-6, and IL-1beta in injured-tissue models.
How does TB-500 (thymosin beta-4 fragment) work mechanistically?
The core mechanism is G-actin sequestration. Thymosin beta-4 — and its LKKTETQ fragment — binds monomeric (globular) actin so it is not available to polymerize into filaments, regulating the actin cytoskeleton dynamics that drive cell migration. Downstream, the peptide activates integrin-linked kinase, forms a functional complex with PINCH, and stimulates the Akt survival pathway. In the cardiac literature, this mechanism translated into enhanced cardiomyocyte survival and improved cardiac function after coronary artery ligation in mice [9]. In the dermal literature, the same cytoskeletal mechanism is implicated in accelerated wound closure and re-epithelialization across rodent models and Phase 2 trials [12].
Has any study directly compared the blend against either peptide alone?
No. The 2025 mechanism reviews of BPC-157 and the published commentary on the BPC-157 + TB-500 combination both note that additive effects are plausible on mechanism, because the pathways are non-overlapping, but that no controlled in-vivo study has directly compared the blend against monotherapy. The 2025 BPC-157 scoping review reported three published human pilot studies of BPC-157 alone; for the BPC-157 + TB-500 blend specifically, the count is zero [16][18].
What research doses have been used for BPC-157 and TB-500 in animal studies?
BPC-157 in rodent models was most commonly studied at 10 μg/kg intraperitoneal once daily across the Sikiric-lab tendon, ligament, muscle, and gastrointestinal work, with parallel arms at 10 ng/kg and occasionally 10 pg/kg [1][3]. Topical use in rodents was at 1 μg dissolved per gram of neutral cream; oral use was at approximately 0.16 μg/mL in drinking water [2]. TB-500 / thymosin beta-4 in the rat stroke model was administered at 6 mg/kg intraperitoneal, first 24 hours after middle-cerebral-artery occlusion then every three days for four doses [11]; in mouse cardiac models, 150 μg per mouse intraperitoneal was used [10]. Human ophthalmic trials of thymosin beta-4 used 0.1% topical solution dosed five to six times daily for several weeks [14][15].
What is the half-life of BPC-157?
BPC-157's plasma half-life in preclinical work is reported as under 30 minutes, with hepatic metabolism and renal clearance. Thymosin beta-4 is also short-lived in circulation. The 2025 scoping review of BPC-157 in musculoskeletal healing cited this short half-life as a key limitation for translational dosing — repeated administration is required to maintain any plasma exposure, and how brief systemic peaks translate to the tissue-level regenerative effects in animal models is not fully resolved [16].
Is the Wolverine stack safe in research models?
The preclinical safety profile of both peptides in animal studies has been characterized as favorable in the published reviews, including the 2025 literature and patent review and the 2025 musculoskeletal scoping review [16][17]. That preclinical signal does not establish human safety. Theoretical concerns for chronic dosing include pathologic (non-physiologic) angiogenesis, immunogenicity from peptide impurities in compounded products, and unknown long-term effects on tissues with high resident progenitor populations. None of these has been characterized in adequately powered human studies of either peptide, let alone the blend.
Does the site sell the Wolverine blend?
No. Wolverine Clinic is an independent editorial project that summarizes the research literature on the BPC-157 + TB-500 blend. It does not sell, manufacture, distribute, broker, or refer for any product. It is not affiliated with any vendor or compounding pharmacy. The site does not link to vendors, does not run affiliate offers, and does not collect orders. All citations point to primary research sources — PubMed, PubMed Central, peer-reviewed journals — not commercial vendors.
Is Wolverine Clinic a real clinic?
No. Despite the 'clinic' in the domain name, Wolverine Clinic is not a medical clinic and does not provide clinical services. It does not employ clinicians and does not offer consultation, prescription, diagnosis, or treatment. The 'clinic' modifier here is editorial framing — a position the publisher occupies relative to the published research literature, not a claim about clinical services. The /about page describes the editorial standards and entity behind the site in more detail.
Where does the BPC-157 research literature come from?
The large majority of the BPC-157 preclinical literature originates from the laboratory of Predrag Sikiric and Sven Seiwerth in Zagreb, Croatia, who first described the peptide in the 1990s. The same group developed the compound under the names PL-10, PLD-116, and PL 14736, and advanced it through Phase 2 trials for inflammatory bowel disease under Pliva (Croatia) before the program was discontinued without proceeding to approval [7]. Independent replication of the major preclinical findings outside the Sikiric group is comparatively sparse — a point flagged by the 2025 scoping review as a limitation of the evidence base [16].